On April 4, medical AI company Coreline Soft announced that its AI-based integrated thoracic diagnostic system, AVIEW LCS Plus, is gaining recognition and trust in global markets.
AVIEW LCS Plus is a system that simultaneously analyzes the "BIG3" thoracic diseases—lung cancer, cardiovascular disease, and COPD—through a single CT scan.
Lung cancer remains one of the most deadly diseases in our society. In 2023, there were a total of 85,271 cancer-related deaths, with lung cancer accounting for 21.9% of all cancer deaths, translating to 18,646 individuals. In response, government agencies and the medical community have been continuously working to improve early detection of lung cancer, leading to the launch of the world’s first national lung cancer screening program in 2019. As a result, the sensitivity (detection rate) of lung cancer screening has exceeded 80%.
Previously, thoracic CT screenings focused solely on lung cancer detection. However, utilizing AVIEW LCS Plus has evolved this approach to provide a comprehensive assessment of overall lung health and identify incidental findings early on. The product is now being implemented in national lung cancer screening projects in Germany, Italy, and five countries in Europe, demonstrating the reliability of AI technology in global public health policy.
Professor Jin Guk-yong of the Department of Radiology at Jeonbuk National University Hospital, who also serves as President of the Korean Society of Thoracic Radiology, stated, “With increasing threats to lung health due to complex factors such as fine dust and smoking history, accurate early diagnosis of lung cancer using low-dose chest CT and AI is crucial not only for survival rates but also for quality of life. The focus of patient care is shifting towards prevention and integrated diagnostics, and we will strive to contribute at this pivotal moment.”
Meanwhile, the World Health Organization (WHO) reports that one-third of cancer cases can be prevented through lifestyle changes, another third can be cured through early diagnosis and treatment, and the remaining third can have their symptoms alleviated with proper treatment, thereby advocating for early diagnosis.
